Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNCT with SPM-011 for recurrent high-grade meningioma
jRCT2051190044Phase 2Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Sep 2019
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in meningioma comparing BNCT with SPM-011 with Best supportive care (2 arms). Primary endpoint: Progression-free survival by Macdonald assessment. Started Sep 2019; status: completed.
02
Drugs
borofalan
03
Conditions
meningioma
Beyond the preview
Go deeper on jRCT2051190044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051190044.